Trial Profile
An Observational Study of Cetuximab with Platinum-based Chemotherapy for First-line Treatment in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2017
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ENCORE
- 13 Oct 2017 New trial record
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress